Literature DB >> 8187341

Modulation of the IL-2 production defect in vitro in Graves' disease.

Z Eisenstein1, E Engelsman, M Weiss, Y Kalechman, B Sredni.   

Abstract

IL-2 production by mitogen-induced peripheral blood mononuclear cells was reported to be reduced in several autoimmune diseases, including Graves' disease (GD). This production defect in hyperthyroid GD was restored to normal by antithyroid drug therapy or during remission. However, its underlying mechanism and role in the autoimmune process are still uncertain. The present study was undertaken in order to screen the in vitro IL-2 generating system for putative factors responsible for its failure, and to see to what extent this was reversible. Thyroid hormone or antithyroid drugs had no effect on IL-2 production in vitro. Cultures were found to be free of soluble inhibitors of IL-2 production or action. IL-1 deficiency as a cause of the IL-2 defect was ruled out; rather, Graves' adherent cells were found to be activated in being capable of secreting large amounts of IL-1 and prostaglandin E2 (PGE2). The latter was not found to be responsible for the decreased IL-2 production. IL-2 production by Graves' mononuclears was completely restored to normal by: (i) adherent cell depletion, irradiation or substitution with normal adherent cells; (ii) preincubation of mononuclears for 24-72 h before mitogen stimulation; (iii) the synergistic action of a phorbol ester and a calcium ionophore. These data indicate that inhibition by activated adherent cells accounts for the in vitro IL-2 production defect in GD. This inhibition is not mediated by soluble factors, but probably through direct interaction with the producing cells, and is reversible in rested cultures or through a bypassed signal transduction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187341      PMCID: PMC1534893          DOI: 10.1111/j.1365-2249.1994.tb06561.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Anti-thyroid drugs and lymphocyte function. II. The in vivo effect on blastogenesis and suppressor cell activity in Graves' disease.

Authors:  N Goldrath; J Shoham; H Bank; Z Eisenstein
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

2.  A comparison of PGE2 effects on human suppressor cell function and on interleukin 2 function.

Authors:  A B Tilden; C M Balch
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

Review 3.  The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses.

Authors:  J J Farrar; W R Benjamin; M L Hilfiker; M Howard; W L Farrar; J Fuller-Farrar
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

4.  The mechanism of inhibition of human IL 2 production.

Authors:  S Chouaib; D Fradelizi
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

5.  Pharmacodynamics of propylthiouracil in normal and hyperthyroid subjects after a single oral dose.

Authors:  J F McMurry; P F Gilliland; C R Ratliff; P D Bourland
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

6.  The liver of MRL/lpr mice contains defective accessory cells and a population of immunosuppressive lymphocytes.

Authors:  D B Magilavy; D A Rowley; M Davis
Journal:  Cell Immunol       Date:  1990-02       Impact factor: 4.868

7.  Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; D Alarcón-Segovia
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

8.  Carbimazole and the autoimmune response in Graves' disease.

Authors:  A M McGregor; M M Petersen; S M McLachlan; P Rooke; B R Smith; R Hall
Journal:  N Engl J Med       Date:  1980-08-07       Impact factor: 91.245

9.  Anti-thyroid drugs and lymphocyte function. I. The in vitro effect on blastogenesis and suppressor cell activity.

Authors:  N Goldrath; Z Eisenstein; H Bank; J Shoham
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

10.  Studies of thyroid hormone and methimazole levels in patients with Graves' disease on a standardized anti-thyroid drug regimen.

Authors:  P A Dahlberg; F A Karlsson; B Lindström; L Wide
Journal:  Clin Endocrinol (Oxf)       Date:  1981-06       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.